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Abstract
Background: Dengue is associated with explosive urban epidemics and has become a major public health problem in many
tropical developing countries, including Brazil. The laboratory diagnosis of dengue can be carried out using several
approaches, however sensitive and specific assays useful to diagnose in the early stage of fever are desirable. The flavivirus
non-structural protein NS1, a highly conserved and secreted glycoprotein, is a candidate protein for rapid diagnosis of
dengue in endemic countries.
Methodology/Principal Findings: We aimed to evaluate the potential use of 3 commercial kits in a panel of 450 serum
samples for early diagnosis of dengue in Brazil. The PanBio Early ELISA (PanBio Diagnostics) showed a sensitivity of 72.3%
(159/220) and a specificity of 100%, while the sensitivity of the Platelia
TM NS1 assay (Biorad Laboratories) was 83.6% (184/
220). However, the highest sensitivity (89.6%; 197/220) was obtained by using the NS1 Ag Strip (Biorad Laboratories). A
lower sensitivity was observed in DENV-3 cases by all 3 kits. Serum positive by virus isolation were more often positive than
cases positive by RT-PCR by all three assays and a higher detection rate was observed during the first four days after the
onset of the symptoms. The presence or absence of IgM showed no influence in the confirmation by the pan-E Early ELISA
(P=0,6159). However, a higher confirmation by both Platelia
TM NS1 (Biorad) and Dengue NS1 Ag Strip (Biorad) in the
absence of IgM was statistically significant (P,0,0001 and P=0,0008, respectively). Only the Platelia
TM NS1 test showed a
higher sensitivity in confirming primary infections than secondary ones.
Conclusions/Significance: The results indicate that commercial kits of dengue NS1 antigen are useful for the laboratory
diagnosis of acute primary and secondary dengue. It can be used in combination with the MAC-ELISA for case detection and
as screening test to complement viral isolation.
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Introduction
Dengue is associated with explosive urban epidemics and has
become a major public health problem [1]. Annually, the World
Health Organization estimates that 50–100 million people are
infected with dengue virus (DENV) worldwide with estimated
250,000–500,000 cases of dengue haemorrhagic fever (DHF) and
dengue shock syndrome (DSS) with about 25,000 deaths
occurring. One or more of four serotypes of DENV (DENV1–
4), a mosquito-borne, positive-strand RNA virus in the genus
Flavivirus, family Flaviviridae cause the disease in more than 100
endemic countries in tropical areas [2].
The geographical spread of all four DENV serotypes through-
out the subtropical regions of the world has led to larger and more
severe outbreaks and the accurate and efficient diagnosis of the
disease is important for clinical care, surveillance, pathogenesis
studies and vaccine research. Furthermore, an efficient diagnosis is
an important tool to support Epidemiological Surveillance
Programs considering the difficulties in confirming dengue cases
based only on the clinical symptoms, especially during inter-
epidemic periods.
Dengue is an enveloped virus with a single-stranded, positive
sense RNA genome of about 11 kb containing a single open
reading frame enconding a single polyprotein co- and pos-
translationally cleaved into 3 structural (C, prM and E) and 7
nonstructural proteins (NS1, NS2A, NS2B, NS, NS4A, NS4B and
NS5) [3].
Dengue is a major public health problem in many tropical and
subtropical countries in the world. The accurate and efficient
diagnosis of dengue is important for clinical care, surveillance,
pathogenesis studies, and vaccine research.
The most used techniques use for dengue serodiagnosis are
based on the anti-DENV IgM and IgG detection by using MAC-
ELISA and IgG-ELISA [4]. However, one of the limitations
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phase of the disease. Usually, it takes from 3 to 5 days after the
onset of the symptoms to detect anti-DENV IgM and from 1 to 14
days to anti-DENV IgG to become detectable, depending on
whether the patient has primary or secondary infections [5].
During the acute phase, however, the NS1 exists as secreted as
well as a membrane-associated protein and both forms are
demonstrated to be immunogenic [6,7,8,9,10]. High NS1 level
was demonstrated to circulate in the acute phase of dengue by
antigen capture ELISAs, found in the sera of patients with primary
and secondary DENV infections, up to the ninth day after the
onset of the symptoms [10,11].
The availability of commercial kits for the detection of anti-
DENV NS1 in acute serum provides an alternative to the existing
methods such as PCR, serology and virus isolation. Previous
studies have shown the sensitivity and specificity of NS1 capture
commercial kits for the laboratorial diagnosis of dengue infections
[12,13,14,15,16,17,18,19].
Recently, the Brazilian Ministry of Health has establish this new
approach in sentinel clinics throughout the country after the 2008
dengue epidemic, however without a full evaluation of the
commercial tests available. In the study, we aimed to evaluate
the sensitivity and specificity of 3 commercially-available dengue
NS1 antigen kits to demonstrate its potential use for the early
laboratory confirmation of acute dengue infection in Brazil. This
constitutes the first report of a comparison of NS1 antigen capture
assays performed in the country.
Materials and Methods
Ethics statement
The samples belong to a previously-gathered collection from an
ongoing Project in the Laboratory approved by the Ethics
Committee on Human Research (CEP: 274/05).
Dengue cases and non- dengue cases definitions
Laboratory-positive DENV infection was defined in patients
experiencing a febrile illness consistent with dengue according to
WHO criteria [20] in which infection was confirmed by DENV
isolation [21], detection of DENV RNA by RT-PCR [22],
detection of anti-DENV IgM antibodies by MAC-ELISA[23],
and/or a .4-fold rise in anti-DENV IgG-ELISA titer in paired
acute and convalescent sera [24]. Individuals negative for DENV
infection by using all the methods described above and health




thafter theonset of the symptoms)
analyzed in this study by the pan-E Early ELISA (PanBio
Diagnostics, Brisbane, Australia- first generation), Platelia
TM (Biorad
Laboratories, Marnes-La-Coquette, France) and NS1 Ag Strip
(Biorad Laboratories, Marnes-La-Coquette, France) belong to a
previously-gathered serum collection of the Laboratory of Flavivirus
at Oswaldo Cruz Institute, FIOCRUZ, Brazil, from epidemics
occurred from 1986 to 2008. A panel of 450 sera (220 dengue
positive sera and 230 non-dengue sera) was divided into eleven
Groups as follows: Groups A to C, sera from patients infected with
DENV-1 (n=50), DENV-2 (n=50), and DENV-3 (n=58),
respectively; Group D, sera from patients with dengue infection
serologicallyconfirmedbyMAC-ELISAwithnegativevirusisolation
and RT-PCR (n=62); Group E, sera from healthy individuals
(n=30); Group F, sera from individuals negative for dengue (n=86);
Group G, sera from yellow fever positive individuals (n=20);Group
H, sera from individuals vaccinated for yellow fever and negative for
anti-DENV antibodies (n=44); Group I, sera from measles patients
(n=16) and Group J, sera from rubella patients (n=34).
Dengue virus isolation
Virus isolation was performed by inoculation into C6/36 Aedes
albopictus cell line [21] and isolates were identified by indirect
fluorescent antibody test (IFAT) using serotype-specific monoclo-
nal antibodies [25].
Reverse transcriptase (RT) –PCR
RT—PCR for detecting and typing DENV was performed as
described previously [22]. Briefly, consensus primers were used to
anneal to any of the four DENV types and amplify a 511-bp
product in a reverse transcriptase-polymerase reaction. A cDNA
copy of a portion of the viral genome was produced in a reverse
transcriptase reaction. After a second round of amplification
(nested PCR) with type-specific primers, DNA products of unique
sizes for each DENV serotype were generated and analyzed by gel
electrophoresis.
Immunoglobulin M (IgM) antibody capture ELISA
(MAC-ELISA)
The in-house MAC-ELISA was carried out for dengue cases
confirmation as described previously [23].
Immunoglobulin G (IgG) antibody detection ELISA (IgG—
ELISA)
The IgG—ELISA previously described by Miagostovich [24]
was performed for the characterization of dengue immune
response as primary or secondary infections in dengue cases
previously confirmed by virus isolation, RT—PCR and/or MAC-
ELISA. Briefly, 96-well plates were coated with hyper immune
ascitic fluid (a mixture of anti-DENV-1 to 4), followed by the
addition of a mixture of the four DENV antigens. Serum diluted
1:40 was added to the first well and four-fold dilutions were carried
out up to the eighth well. After incubation, anti-human IgG
conjugated to horseradish peroxidase was added Acute phase
serum samples (,6 days after onset of symptoms) with IgG-ELISA
titers of 1:160 or greater are considered to be secondary infections.
Author Summary
Dengue is the one of the most prevalent arthropod-borne
viral diseases in tropical regions of the world. Manifesta-
tions may vary from asymptomatic to potentially fatal
complications. Laboratorial diagnosis is essential to diag-
nose dengue and differentiate it from other diseases.
Dengue virus non-structural protein 1 (NS1) may be used
as a marker of acute dengue virus infection. Our results,
based in the comparison of three NS1 antigen capture
assays available, have shown that this approach is reliable
for the early diagnosis of dengue infections, especially in
the first four days after the onset of the symptoms. A lower
sensitivity was observed in DENV-3 cases. Serum positive
by virus isolation were more often detected than those
positive by RT-PCR by all three assays. Only the Platelia
TM
NS1 test showed a higher sensitivity in confirming primary
infections than secondary ones. In conclusion, NS1 antigen
capture commercial kits are useful for diagnosis of acute
primary and secondary dengue infections and, in endemic
countries where secondary infections are expected to
occur, may be used in combination with MAC-ELISA to
increase the overall sensitivity of both tests.
Early Diagnosis of Dengue in Brazil
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960 on days 10–15 after onset are secondary responses.
NS1 antigen capture assays
pan-E DENGUE EARLY ELISA (PanBio Diagnostics,
Brisbane, Australia). This first generation test is based on a
one-step sandwich format microplate enzyme immunoassay to
detect DENV NS1 antigen in human sera. The test uses
horseradish peroxidase conjugated anti-NS1 monoclonal
antibody with preservative. If NS1 antigen is present in the
sample, an immune-complex MAb-NS1-MAb/peroxidase will be
formed. The acute serum specimens were allowed to thaw to
laboratory ambient temperature (21–22uC). Briefly, 100 mL
diluted test samples and controls were pipetted into their
respective microwells and incubated for 60 min at 37uC. After a
six-time washing steps, 100 mL HRP conjugate anti-NS1 MAb
were pipetted into each well and plate was incubated for 60 min at
37uC. After a six-times washing step, 100 mL of substrate was
added into each well and incubated for 10 min at room
temperature in the dark. The presence of immune-complex was
demonstrated by a color development and the enzymatic reaction
was stopped by adding 100 mL1 MH 3PO4. The optical density
(OD) reading was taken with a spectrophotometer at a wavelength
of 450–620 nm and the amount of NS1 antigen present in an
individual serum sample was determined by comparing the OD of
the sample to the OD of the cut-off control serum. Results were
calculated as ‘‘Panbio units’’ with results ,9.0, 9.0–11.0, and
$11.0 defined as negative, inconclusive, and positive, respectively.
Inconclusive samples were re-tested to confirm the result.
Platelia
TM Dengue NS1 Ag-ELISA (Biorad Laboratories,
Marnes-La-Coquette, France). The test is based on a one-step
sandwich format microplate enzyme immunoassay to detect
DENV NS1 antigen in human serum or plasma. The assay uses
murine monoclonal antibody for capture and revelation. If NS1
antigen is present in the sample, an immune-complex MAb-NS1-
MAb/peroxidase will be formed. Briefly, the acute serum
specimens were allowed to thaw to laboratory ambient
temperature (21–22uC). Sample diluent (50ml), respective samples
and controls (50 ml each) and 100 ml of diluted conjugate were
incubated for 90 min at 37uC within the respective microplate
wells coated with purified mouse anti-NS1 monospecific
antibodies. After a six-times washing step, 160ml of substrate was
added into each well and incubated for 30 min at room
temperature in the dark. The presence of immune-complex was
demonstrated by a color development and the enzymatic reaction
was stopped by adding 100ml1 NH 2SO4. The optical density (OD)
reading was taken with a spectrophotometer at a wavelength of
450–620 nm and the amount of NS1 antigen present in an
individual serum sample was determined by comparing the OD of
the sample to the OD of the cut-off control serum.
Dengue NS1 Ag STRIP (Biorad Laboratories, Marnes-La-
Coquette, France). Dengue NS1 Ag STRIP is an immu-
nochromatographic test (ICT) for the rapid detection of NS1
antigen. Briefly, one drop of migration buffer was added to 50 mL
serum in a specimen tube and a strip was placed in the tube. The
strip has two lines: a control line (C) (‘biotin – gold colloidal
particles coated with streptavidin’ complex) and a test line (T)
(‘monoclonal anti-NS1 antibodies (mAb) – NS1 Ag – gold colloidal
particles coated with anti-NS1 mAb’ complex). The appearance of
the T and C lines after a migration time of 15 minutes (min)
indicates a positive result. The appearance of the C line alone
indicates a negative result. If the C line is not present, the test is
considered invalid and is repeated. It is recommended that strips
giving ambiguous (faint color at the T line) or negative results are
put back in the tube after the initial reading and left for a further
15 min for re-evaluation. We evaluated all samples at 15 min
(ICT 15 min) and then at 30 min (ICT 30 min).
Data and statistical analysis
The sensitivities, specificities, efficiency, negative and positive
predicted values were calculated as follows:
Sensitivity: a/a+c X 100%
Specificity: d/d+b X 100%
Efficiency: a+d/a+b+c+d X 100%
Negative Predicted Value: d/d+c X100%
Positive Predicted Value: a/a+b X 100%; where: a=number of
true positive, b=number of false positive, c=number of false
negative and d=number of true negative.
The derived data was tabulated in appropriate worksheets using
the Microsoft Excel and evaluated by chi-square test using the Epi
Info 6 (Center for Disease Control and Prevention, Atlanta) for
any statistical significant association.
Results
Overall sensitivities of the NS1 antigen capture tests
A panel of 450 (n=220 dengue cases and n=230 non-dengue
cases) was used to evaluate three NS1 antigen capture tests
commercially available. The overall sensitivities were 72.3% (159/
220) for the pan-E Early ELISA (PanBio) test, 83.6% (184/220) for
the Platelia
TM NS1 (BioRad) kit, and 89.6% (197/220) for the
NS1 Ag Strip kit (BioRad), Table 1. The differences observed in
the sensitivities between the three kits analyzed were statistically
significant (P=0.0009).
NS1 sensitivities in relation to viral serotype
The pan-E Early ELISA (PanBio) showed a higher sensitivity in
confirming DENV-2 infections (Group B; 82.0%) than confirming
DENV-1 and DENV-3 infections. The Platelia
TM NS1 kit
(BioRad) was more sensitive in the detection of DENV-1 cases
(Group A; 98.0%) than in the detection of DENV-2 and DENV-3
infections. The Dengue NS1 Ag Strip kit (BioRad) showed the
same sensitivity in confirming DENV-1 and DENV-2 infections
(98.0%). DENV-3 infections were the detected less often by all the
three kits tested (65.5%, 86.2% and 88.0% for the pan-E Early
ELISA (PanBio), the Platelia
TM NS1 kit (BioRad) and the Dengue
NS1 Ag Strip kit (BioRad), respectively (Table 1).
NS1 specificities and cross-reactivity in patients with
other confirmed diagnoses and yellow fever vaccination
Specificities were 100%, 98.7% and 99.1% for the PanBio kit,
for the Platelia
TM NS1 kit (Biorad) and for the NS1 Ag Strip
(BioRad), respectively, based on the analysis of sera of healthy
individuals (Group E) and individuals negative for dengue (Group
F), Table 1. No cross-reactivity was observed with sera from yellow
fever infected patients (Group G); however both Biorad kits
showed cross-reactivity with one yellow fever vaccinee (Group H).
None of the measles sera (Group I) were recognized by the NS1
tests. One rubella positive case (Group J) showed cross-reactivity
with both Platelia
TM NS1 kit (Biorad) and for the NS1 Ag Strip
(BioRad) kit. The overall evaluations according to the different
Groups analyzed are shown in Table 1.
NS1 sensitivities according to the different acute
diagnosis methods
A higher sensitivity (71.5%, 94.8% and 98.7%) was observed in
cases positive by virus isolation only than in cases previously
Early Diagnosis of Dengue in Brazil
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Early ELISA, Platelia
TM NS1 and Dengue NS1 Ag Strip,
respectively (Table 2).
NS1 sensitivities in the presence and absence of IgM
The detection rate by the pan-E Early ELISA, Platelia
TM NS1
and Dengue NS1 Ag Strip in the presence of IgM was 69.4%,
64.5% and 77.4%, respectively (Table 2). In this study, the
presence or absence of IgM did not influence detection by the pan-
E Early ELISA (P=0,6159). However, a higher detection rate by
both Platelia
TM NS1 (Biorad) and Dengue NS1 Ag Strip (Biorad)
in the absence of IgM was statistically significant (P,0,0001 and
P=0,0008, respectively).
Sensitivities of the NS1 tests by the number of days after
the onset of the symptoms
The sensitivities of all NS1 tests were evaluated according to the
number of days of illness. A higher detection rate by the three tests
analyzed was during the first four days after the onset of the
symptoms (Day 3, in Figure 1, considering day 0 as the first day of
fever). The sensitivity of Platelia
TM NS1 (Biorad) decreased to 75%
of detection after that and maintained the same rate until day 6 of
illness. However, after the 4
th day, the NS1 Ag Strip (Biorad)
showed 89.0% of sensitivity up to the 7
th of symptoms. From day
five to the 7
th, the pan-E Early ELISA (Panbio) confirms about
60.0% of the cases (Figure 1). Although dengue NS1 antigen
detections up to the 9
th day are observed, here we plotted cases
only up to the 7
th day due to the low number of samples
representing 8
th and 9
th days in our population.
We also aimed to compare the cases confirmation by the dengue
NS1 antigen capture to the confirmation by other methodologies
used in this study according to the number of the days of illness. In
this comparison, we considered a NS1 positive case, as a case
positive in any of the three tests used. Figure 2 shows NS1
confirmation around 90% of the cases up to the 7
th day of illness,
as previously shown. RT-PCR and virus isolation detections rate
Table 1. Sensitivity and specificity of 3 commercially available kits for NS1 antigen capture in dengue sera and controls.
NS1 antigen capture kit
No. of sera with indicated result/total no. tested
b
Groups
a pan-E DENGUE EARLY ELISA Platelia
TM Dengue NS1 Ag-ELISA Dengue NS1 Ag STRIP
Negative Positive Negative Positive Negative Positive
A (DENV1 cases; n=50) 13/50 (26.0) 37/50 (74.0) 1/50 (2.0) 49/50 (98.0) 1/50 (2.0) 49/50 (98.0)
B (DENV2 cases; n=50) 9/50 (18.0) 41/50 (82.0) 5/50 (10.0) 45/50 (90.0) 1/50 (2.0) 49/50 (98.0)
C (DENV3 cases; n=58) 20/58 (34.5) 38/58 (65.5) 8/58 (13.8) 50/58 (86.2) 7/58 (12.0) 51/58 (88.0)
D (IgM positive cases; n=62) 19/62 (31.0) 43/62 (69.0) 22/62 (35.5) 40/62 (64.5) 14/62 (22.6) 48/62 (77.4)
Total of Groups A–D 61/220 (27.7) 159/220 (72.3) 36/220 (16.4) 184/220 (83.6) 23/220 (10.5) 197/220 (89.5)
E (healthy individuals; n=30) 30/30 (100) 0/30 30/30 (100) 0/30 30/30 (100) 0/30
F (individuals negative for dengue; n=86) 86/86 (100) 0/86 85/86 (98.8) 1/86 86/86 (100) 0/86
G (yellow fever positive cases; n=20) 20/20 (100) 0/20 20/20 (100) 0/20 20/20 (100) 0/20
H (individuals vaccinated for yellow fever; n=44) 44/44 (100) 0/44 43/44 (97.7) 1/44 43/44 (97.7) 1/44
I (measles cases; n=16) 16/16 (100) 0/16 16/16 (100) 0/16 16/16 (100) 0/16
J (rubella cases; n=34) 34/34 (100) 0/34 33/34 (97.0) 1/34 33/34 (97.0) 1/34
Total of Groups E–J 230/230 (100) 0/230 227/230 (98.7) 3/230 228/230 (99.1) 2/230
aSubjects in groups A to D had confirmed DENV infection; subjects in groups E to J had no DENV infection.
bValues in parentheses are percentages.
doi:10.1371/journal.pntd.0000738.t001
Table 2. Sensitivities of 3 NS1 antigen capture assays in patients with clinical diagnosis of acute dengue confirmed by RT-PCR and/
or virus isolation and by MAC-ELISA.
NS1 antigen capture kits
No. of sera with indicated result/total no. tested
a
Dengue case confirmation pan-E DENGUE EARLY ELISA Platelia
TM Dengue NS1 Ag-ELISA Dengue NS1 Ag STRIP
RT-PCR only (n=45) 28/45 (62.3) 37/45 (82.3) 37/45 (82.3)
Virus isolation only (n=77) 55/77 (71.5) 73/77 (94.8) 76/77 (98.7)
RT-PCR and virus isolation (n=36) 33/36 (91.7) 34/36 (94.5) 36/36 (100)
MAC-ELISA only 43/62 (69.4) 40/62 (64.5) 48/62 (77.4)
Total 159/220 (72.3) 184/220 (83.6) 197/220 (89.6)
aValues in parentheses are percentages.
doi:10.1371/journal.pntd.0000738.t002
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that. However, on the other hand IgM detection rates increase
only after the 4
th day of illness.
NS1 sensitivity in primary and secondary infections
The serologic response could be characterized by IgG-ELISA in
54 samples, where a second specimen was available. There were
40 primary and 14 secondary infections. No differences were
observed by the pan-E Early ELISA (Panbio) (P=0.96) and by the
NS1 Ag Strip (Biorad) (P=0.76) in confirming primary and
secondary infections (Table 3). However, the Platelia
TM NS1 test
showed a higher sensitivity in confirming primary infections than
secondary ones (P=0.01).
NS1 tests efficiency and predicted values
In our study, the pan-E Early ELISA test (Panbio) was less
efficient in detecting acute dengue infections (86.1%) when
compared to the Platelia
TM NS1 test (91.3%) and the NS1 Ag
Strip (95.0%). Positive predictive values were 98.3%, 99.5% and
100% for the Platelia
TM NS1 (Biorad), NS1 Ag Strip (Biorad) and
pan-E Early ELISA tests (Panbio), respectively. However, the pan-
E Early ELISA (Panbio) showed the lowest negative predictive
value (78.3%), followed by the Platelia
TM NS1 test (Biorad) with
86.3% and the NS1 Ag Strip (Biorad) with 91.1% (Table 4).
Discussion
The techniques of dengue serologic diagnosis which have been
widely used are based on the detection of IgM antibodies by
MAC-ELISA and IgG by IgG-ELISA. However, one of the
limitations of these techniques is the inability to detect antibodies
to DENV in the acute phase of disease [5,26]. It takes 3 to 5 days
for IgM antibodies and anti-DENV 10–14 days for IgG anti-
DENV to become detectable. Moreover, primary and secondary
infections have different profiles of production of these antibodies
[27].
According to previous studies the presence of NS1 in human
sera can be confirmed between days 0 to 9 [28,29,30] and with a
peak at days 6 to 10 [31]. Currently, commercial kits such as the
Dengue EARLY ELISA (Panbio Diagnostics, Brisbane, Australia),
Platelia
TM Dengue NS1 Ag-ELISA and Dengue NS1 Ag STRIP
(BioRad Laboratories Marnes La Coquette, France) are available
for early diagnosis of dengue based on NS1 antigen capture and
several studies have been conducted in many laboratories
[12,15,18,19,29,31,32,33,34,35,36].
In this study, we had the opportunity to evaluate and compare
three NS1 antigen capture kits available with a panel of samples
(n=450) from cases occurred since the introduction of dengue in
Rio de Janeiro, Brazil in 1986 to 2008. The NS1 Ag Strip test
(Biorad) was the most sensitive in confirming dengue cases,
Figure 1. Sensitivity of 3 commercial dengue NS1 capture assays according to the number of days of illness (n=220).
doi:10.1371/journal.pntd.0000738.g001
Figure 2. Overall sensitivity of positive results in any NS1 antigen capture assay compared to dengue diagnosis by MAC-ELISA,
virus isolation and RT-PCR according to the number of days after onset of illness.
doi:10.1371/journal.pntd.0000738.g002
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TM NS1 (BioRad). The least sensitive was the
pan-E Early ELISA (PanBio) with 72.3% of sensitivity. However,
in this study PanBio kit was the most specific (100%) while both
kits from BioRad showed 98.7% and 99.1% of specificity,
respectively. A recent evaluation in Malaysia showed that the
NS1 Ag Strip had 90.4% of sensitivity and 99.5% of specificity
[17]. Studies performed in Vietnam [18] and French Guyana [29]
showed sensitivities of 82% and 88%, respectively for the
Platelia
TM NS1 test. However, sensitivities varying from 63.2%
to 93.3% have also been reported for this kit [12,15]. Even though
different DENV genotypes may circulate in the Americas and
Asia, NS1 kits evaluations in countries from those area show the
ability of those tests to detect DENV in infected patients. Our
observations are consistent with previous studies in which the pan-
E Early ELISA had lower sensitivities [13,14,16,37]. However, to
increase diagnostic performance, Panbio has recently released an
improved second generation for their NS1 capture kit with
changes in key reagents and procedure [38].
All NS1 tests were more sensitive in confirming cases positive by
virus isolation than in cases positive by RT-PCR. Dussart [29]
confirmed 94.1% of cases positive by virus isolation and 85% of
the cases RT-PCR positive using the Platelia
TM NS1 test.
Recently, McBride [16] showed that the NS1 antigen capture
was positive in 87% of the cases positive by RT-PCR. In our
study, the Dengue NS1 Ag Strip confirmed 98.7% of the cases
positive by virus isolation and 82.3% of RT-PCR positive cases,
results similarly observed by Zainah [17]. In the presence of IgM
antibodies, the Dengue NS1 Ag Strip confirmed more cases
(77.4%) than the pan-E Early ELISA (69.4%) and the Platelia
TM
NS1 (64.5%). The presence or absence of IgM did not influence in
the cases confirmation by the pan-E Early ELISA (P=0,6159).
However, the higher confirmation by both Platelia
TM NS1 and the
Dengue NS1 Ag Strip in the absence of IgM were statistically
significant. Sekaran [32] showed that the NS1 detection rates
decrease as IgM levels rise, in agreement with our results.
The pan-E Early ELISA (PanBio) showed a higher sensitivity in
confirming DENV-2 infections and the Platelia
TM NS1 kit
(BioRad) in DENV-1 infections. However, the Dengue NS1 Ag
Strip kit (BioRad) showed the same sensitivity in confirming
DENV-1 and DENV-2 infections. DENV-3 infections were the
least confirmed by all three kits. The apparent inability in
confirming infection by this serotype has been shown previously
[33]. Furthermore, differences in the inter-serotype sensitivities
have been reported for all three kits. McBride [16] recently
showed lower sensitivities by the pan-E Early ELISA (PanBio) in
DENV-2 and DENV-4 infections. The latter was also found in
previous studies performed by Bessoff [37] and Dussart [14] and
most recently in a study performed in Venezuela [36]. Due to the
absence of DENV-4 circulating in Brazil, we were not able to
access the assays sensitivities in cases infected by this serotype.
Both Biorad kits (Platelia
TM NS1 and Dengue NS1 Ag Strip)
showed a lower sensitivity in DENV-2 infections from Vietnam
[18] and Venezuela [36].
A higher detection rate by the three tests was found during the
first four days after the onset of the symptoms. Although dengue
NS1 antigen detections up to the 9
th day are described, here we
analyzed cases only up to the 7
th day due to the low number of
samples representing 8
th and 9
th days in our population. The lack
of later samples in this study did not allow us to determine when
NS1 detection would decrease. However, previous studies found
NS1 antigen in 82% to 83% of patients with dengue from day 1 to
9
th after the onset of fever [11,30].
The Platelia
TM NS1 test showed a higher sensitivity in
confirming primary infections than secondary ones, as previously
observed [12,15,17,18,32,34]. False negative results by NS1
antigen capture in secondary infections may also be due to the
immune-complexes formation by the anti- DENV IgG sequestra-
tion [39]. Efforts to dissociate immune complexes by acid
treatment can enhance the assays sensitivities, as previously shown
[15]. However, in our study no attempts were made to dissociate
Table 3. Sensitivities of NS1 antigen capture assays in patients with primary and secondary dengue infections (n=54).
NS1 antigen capture kits
No. of sera with indicated result/total no. tested
a
Patients immune response pan-E DENGUE EARLY ELISA P value Platelia
TM Dengue NS1 Ag-ELISA P value Dengue NS1 Ag STRIP P value
Primary infection (n=40) 26/40 (66.0) 0.96 38/40 (95.0) 0.01 38/40 (95.0) 0.76
Secondary infection (n=14) 09/14 (64.3) 10/14 (71.4) 13/14 (93.0)
aValues in parentheses are percentages.
doi:10.1371/journal.pntd.0000738.t003
Table 4. Sensitivity, specificity, efficiency and predictive values of 3 commercial dengue NS1 capture assays.
NS1 antigen capture tests
pan-E Early ELISA (PanBio) (%) Platelia NS1 (BioRad) (%) NS1 Ag Strip (BioRad) (%)
Sensitivity 72 84 90
Specificity 100 99 99
Efficiency 86 91 95
Positive Predicted Value 100 98 99
Negative Predicted Value 78 86 91
doi:10.1371/journal.pntd.0000738.t004
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confirming secondary cases, a larger number of cases should be
tested.
Among the kits evaluated, the Dengue NS1 Ag Strip (BioRad)
was the most efficient in confirming dengue infections by
capturing NS1 antigen from infected patients. Moreover, it was
more convenient to be used, as the results can be obtained in
15 minutes, easy to perform and its performance does not involve
the use of special laboratory equipment.
Previous studies have demonstrated a diagnostic strategy
combining NS1 Ag detection in acute-phase sera and DENV
IgM detection in early-convalescent-phase sera, providing a
sensitivity of about 90% for dengue diagnosis [29,34].
In conclusion, this evaluation has shown that NS1 antigen
capture assays are indeed an alternative tool for the early diagnosis
of dengue infections, may be used as a screening test prior virus
isolation and used in combination with IgM capture can increase
the rate of cases confirmation, especially in endemic areas where
secondary infections are expected to occur due to the co-
circulation of the different DENV serotypes, such as seen in Brazil.
This evaluation was performed for research purposes only and
authors have no financial interest. The pan-E Early ELISA from
Panbio and the Dengue NS1 Ag Strip from BioRad were kindly
provided for evaluation.
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